What is Vitamin D?
Vitamins are compounds that you must have for growth and health. They are needed in small amounts only and are available in the foods that you eat. Vitamin D is necessary for strong bones and teeth.
Lack of vitamin D may lead to a condition called rickets, especially in children, in which bones and teeth are weak. In adults it may cause a condition called osteomalacia, in which calcium is lost from bones so that they become weak. Your doctor may treat these problems by prescribing vitamin D for you. Vitamin D is also sometimes used to treat other diseases in which calcium is not used properly by the body.
Vitamin D is the form of vitamin D used in vitamin supplements.
Some conditions may increase your need for vitamin D. These include:
- Alcoholism
- Intestine diseases
- Kidney disease
- Liver disease
- Overactivity of the parathyroid glands with kidney failure
- Pancreas disease
- Surgical removal of stomach
In addition, individuals and breast-fed infants who lack exposure to sunlight, as well as dark-skinned individuals, may be more likely to have a vitamin D deficiency. Increased need for vitamin D should be determined by your health care professional.
Alfacalcidol, calcifediol, calcitriol, and dihydrotachysterol are forms of vitamin D used to treat hypocalcemia (not enough calcium in the blood). Alfacalcidol, calcifediol, and calcitriol are also used to treat certain types of bone disease that may occur with kidney disease in patients who are undergoing kidney dialysis.
Claims that vitamin D is effective for treatment of arthritis and prevention of nearsightedness or nerve problems have not been proven. Some psoriasis patients may benefit from vitamin D supplements; however, controlled studies have not been performed.
Injectable vitamin D is given by or under the supervision of a health care professional. Some strengths of Vitamin D and all strengths of alfacalcidol, calcifediol, calcitriol, and dihydrotachysterol are available only with your doctor's prescription. Other strengths of Vitamin D are available without a prescription. However, it may be a good idea to check with your health care professional before taking vitamin D on your own. Taking large amounts over long periods may cause serious unwanted effects.
Vitamin D indications
Dihydrotachysterol is indicated for the treatment of acute, chronic, and latent forms of postoperative tetany, idiopathic tetany, and hypoparathyroidism.
Uses of Vitamin D in details
Use: Labeled Indications
Dietary supplement: As a vitamin D dietary supplement
Off Label Uses
Hypoparathyroidism
Since parathyroid hormone (PTH) is required for the conversion of vitamin D (Vitamin D or cholecalciferol) to the active metabolite of vitamin D (1,25-dihydroxyvitamin D), alternative vitamin D preparations not dependent on this conversion (eg, alfacalcidol, calcitriol) are recommended for routine use. Based on the Endocrine Society guidelines for the Management of Hypoparathyroidism, active vitamin D preparations (ie, alfacalcidol, calcitriol) in conjunction with calcium supplementation is the standard therapy for hypoparathyroidism. Addition of native vitamin D (eg, cholecalciferol or Vitamin D) may be considered for supplemental therapy.
Osteoporosis, prevention
Based on the National Osteoporosis Foundation (NOF) Clinician
Vitamin D description
A vitamin D that can be regarded as a reduction product of vitamin D2.
Vitamin D dosage
Dosage Forms
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Capsule,
Oral:
D3-50: 1.25 MG (50000 UT) [dairy free, egg free, fish derivative free, gluten free, kosher certified, no artificial color(s), nut free, soy free, sugar free, wheat free, yeast free]
Decara: 1.25 MG (50000 UT) [contains fd&c yellow #10 (quinoline yellow), fd&c yellow #6 (sunset yellow), soybean oil]
Decara: 250 MCG (10000 UT) [contains fd&c yellow #10 aluminum lake, fd&c yellow #6 aluminum lake, gelatin (bovine)]
Decara: 625 MCG (25000 UT) [contains soybean oil]
Dialyvite Vitamin D 5000: 125 MCG (5000 UT)
Pronutrients Vitamin D3: 25 MCG (1000 UT) [contains soybean oil]
Weekly-D: 1.25 MG (50000 UT) [contains fd&c red #40]
Generic: 1.25 MG (50000 UT), 250 MCG (10000 UT)
Capsule,
Oral [preservative free]:
D-3-5: 125 MCG (5000 UT) [dairy free, dye free, egg free, gluten free, no artificial color(s), nut free, soy free, sugar free, wheat free, yeast free]
D3-50: 1.25 MG (50000 UT) [dairy free, egg free, fish derivative free, gluten free, kosher certified, no artificial color(s), nut free, soy free, sugar free, wheat free, yeast free]
Generic: 10,000 units, 125 MCG (5000 UT), 25 MCG (1000 UT), 50 MCG (2000 UT)
Liquid,
Oral:
Aqueous Vitamin D: 10 mcg/mL (50 mL) [gluten free, lactose free, sugar free; contains corn oil, methylparaben, polysorbate 80]
Bio-D-Mulsion: 10 mcg/0.03 mL (30 mL [DSC]) [contains sesame oil]
Bio-D-Mulsion Forte: 50 mcg/0.03 mL (30 mL [DSC]) [contains sesame oil]
BProtected Pedia D-Vite: 10 mcg/mL (50 mL) [alcohol free, sugar free; contains polysorbate 80, propylene glycol, sodium benzoate; cherry flavor]
D-Vi-Sol: 10 mcg/mL (50 mL) [gluten free, lactose free, sugar free; contains polysorbate 80]
D-Vita: 10 mcg/mL (50 mL [DSC]) [alcohol free, gluten free, lactose free, sugar free; contains polysorbate 80, propylene glycol, sodium benzoate; fruit flavor]
D-Vite Pediatric: 10 mcg/mL (50 mL) [alcohol free, gluten free, lactose free, no artificial color(s), sugar free; contains disodium edta, polysorbate 80, propylene glycol, saccharin sodium, sodium benzoate]
D3 Vitamin: 10 mcg/mL (50 mL) [contains polysorbate 80, sodium benzoate]
Generic: 10 mcg/mL (50 mL, 52 mL)
Liquid,
Oral [preservative free]:
Generic: 125 mcg/mL (52 mL)
Liquid, Sublingual:
Generic: 5000 units/mL (60 mL)
Tablet,
Oral:
Delta D3: 10 MCG (400 UNIT) [gelatin free, gluten free, lactose free, no artificial color(s), no artificial flavor(s), starch free, sugar free, yeast free]
Dialyvite Vitamin D3 Max: 1.25 MG (50000 UT) [scored]
Vitamin D3 Super Strength: 50 MCG (2000 UT) [gluten free]
Vitamin D3 Ultra Potency: 1.25 MG (50000 UT)
Generic: 10 MCG (400 UNIT), 125 MCG (5000 UT), 20 MCG (800 UNIT), 25 MCG (1000 UT), 50 MCG (2000 UT), 75 MCG (3000 UT)
Tablet,
Oral [preservative free]:
Generic: 5000 units, 10 MCG (400 UNIT), 25 MCG (1000 UT), 50 MCG (2000 UT)
Tablet Chewable,
Oral:
Generic: 10 MCG (400 UNIT)
Tablet Chewable,
Oral [preservative free]:
Generic: 50 MCG (2000 UT)
Dosing: Adult
Note: 1 mcg = 40 units
Hypoparathyroidism (off-label use): Note: Active vitamin D preparations (ie, alfacalcidol, calcitriol) in conjunction with calcium supplementation are recommended therapy. Addition of cholecalciferol (or Vitamin D) may be considered for supplemental therapy (Endocrine Society [Brandi 2016]).
Osteoporosis, prevention (off-label use): Adults ≥50 years of age:
Oral: 800 to 1,000 units/day is recommended, through dietary sources and/or supplementation if needed (NOF [Cosman 2014]).
Vitamin D insufficiency/deficiency treatment (off-label use): Note: Repletion strategies may vary depending on desired target serum 25(OH)D levels as well as the clinical status of the patient. The optimal serum 25(OH)D level is controversial; the Institute of Medicine recommends a 25(OH)D level >20 ng/mL as sufficient in nearly all persons (IOM 2011), whereas others have suggested targeting a level of ~30 ng/mL to minimize the risk of fractures, particularly in patients with osteoporosis (AACE [Camacho 2016]; NOF [Cosman 2014]). However, some data suggest levels >40 ng/mL (median level in one trial: ~48 ng/mL) are associated with increased risk of falls in postmenopausal women (Sanders 2010; Smith 2017).
Therefore, some experts recommend a range of 20 to 40 ng/mL as a reasonable target in most patients (Dawson-Hughes 2018). In patients with normal absorption, for every 100 units/day of cholecalciferol, the serum 25(OH)D level is expected to increase by ~0.7 to 1 ng/mL after a few weeks (ASPEN [McKeever 2017]; Dawson-Hughes 2018). The dose-response declines as the 25(OH)D concentration increases above 40 ng/mL (100 nmol/L) (Dawson-Hughes 2018). The following recommendations are based primarily on expert opinion and clinical experience:
Initial dosing (according to baseline serum 25(OH)D level):
Serum 25(OH)D 20 to 30 ng/mL: Initial: Supplementation dosing:
Oral: 600 to 800 units once daily; a repeat serum 25(OH)D level is not required (Dawson-Hughes 2018) or 1,000 to 2,000 units once daily; may consider a repeat serum 25(OH)D level in ~3 months to determine if the target level has been achieved (Khan 2010).
Serum 25(OH)D 10 to <20 ng/mL: Initial:
Supplementation dosing:
Oral: 800 to 1,000 units once daily (Dawson-Hughes 2018)
or 2,000 units once daily (Khan 2010); a repeat serum 25(OH)D level should be drawn after ~3 months. If target serum 25(OH)D level has not been achieved, may increase to 2,000 units once daily or administer therapeutic dosing of 50,000 units once weekly for 6 to 8 weeks (Dawson-Hughes 2018).OR
Therapeutic dosing (ie, high-dose cholecalciferol):
Oral: 50,000 units once
weekly (or 5,000 to 7,000 units once daily) for ~8 weeks, followed by decreased maintenance dosing as needed to maintain target serum 25(OH)D level (AACE [Camacho 2016]; NOF [Cosman 2014]).Serum 25(OH)D <10 ng/mL or in patients with deficiency symptoms: Initial: Therapeutic dosing (ie, high-dose cholecalciferol):
Oral: 50,000 units once
weekly (or 5,000 to 7,000 units once daily) for 6 to 8 weeks to achieve target serum 25(OH)D level; a repeat serum 25(OH)D level should be drawn after ~3 months to assure target serum 25(OH)D level has been met (AACE [Camacho 2016]; Dawson-Hughes 2018; NOF [Cosman 2014]).Maintenance dosing: Maintenance dosing is highly patient specific and dependent on target 25(OH)D level, and may range from: 600 to 800 units/day (Dawson-Hughes 2018) to 1,000 to 2,000 units/day (AACE [Camacho 2016]; NOF [Cosman 2014]).
Special populations (obese patients, patients on medications known to affect vitamin D metabolism, patients with malabsorption syndromes or gastrectomy): Higher doses or longer durations may be necessary for adequate repletion (AACE [Camacho 2016]; Dawson-Hughes 2018).
Vitamin D deficiency/insufficiency in patients with chronic kidney disease (off-label use):
Oral:
Note: In patients without severe and progressive hyperparathyroidism, including chronic kidney disease stages G3 to G5 and dialysis or transplant patients, KDIGO guidelines recommend correcting vitamin D deficiency and insufficiency with treatment strategies recommended for the general population using cholecalciferol (or Vitamin D) while avoiding hypercalcemia and ensuring phosphate levels are in the normal range. An individualized monitoring approach to direct treatment is also recommended (KDIGO 2009; KDIGO 2017). In patients in whom serum parathyroid hormone levels are progressively rising and remain persistently elevated despite correction of modifiable factors (eg, hyperphosphatemia, vitamin D deficiency), calcitriol or vitamin D analogs are suggested instead of cholecalciferol (or Vitamin D) (KDOQI commentary [Uhlig 2010]).
Dosing: Geriatric
Refer to adult dosing.
Dosing: Pediatric
Vitamin D deficiency, prevention (eg, Rickets prevention): (AAP [Folsom 2017]; AAP [Wagner 2008]; Munns 2016):
Oral:
Breast-fed infants (fully or partially):
Oral: 400 units/day beginning in the first few days of life. Continue supplementation until infant is weaned to ≥1,000 mL/day or 1 qt/day of vitamin D-fortified formula or whole milk (after 12 months of age)
Formula-fed infants ingesting <1,000 mL of vitamin D-fortified formula:
Oral: 400 units/day
Children and Adolescents without adequate intake:
Oral: 400 to 600 units/day.
Note: Children with increased risk of vitamin D deficiency (chronic fat malabsorption, maintained on chronic antiseizure medications) may require higher doses; use laboratory testing [25(OH)D, PTH, bone mineral status] to evaluateVitamin D deficiency, treatment:
Oral:
Note: Treatment should also include calcium and phosphorus supplementation; some patients with chronic fat malabsorption, obesity, or who are maintained on chronic antiseizure medications, glucocorticoids, HIV medications, or antifungals may require higher doses of cholecalciferol (AAP [Golden 2014]); monitor vitamin D status closely.Infants:
Oral: 2,000 units daily for 6 weeks to achieve a serum 25(OH)D level >20 ng/mL; followed by a maintenance dose of 400 to 1,000 units daily. Note: For patients at high risk of fractures a serum 25(OH)D level >30 ng/mL has been suggested (AAP [Golden 2014]).
Children and Adolescents:
Oral: 2,000 units daily for 6 to 8 weeks to achieve serum 25(OH)D level >20 ng/mL; followed by a maintenance dose of 600 to 1,000 units daily. Note: For patients at high risk of fractures a serum 25(OH)D level >30 ng/mL has been suggested (AAP [Golden 2014]).
Vitamin D deficiency in cystic fibrosis, prevention and treatment:
Oral:
CF guidelines (Tangricha [CF Foundation] 2012):
Recommended initial daily intake to maintain serum 25(OH)D level ≥30 ng/mL:
Infants:
Oral: 400 to 500 units/day
Children ≤10 years:
Oral: 800 to 1,000 units/day
Children >10 years and Adolescents:
Oral: 800 to 2,000 units/day
Dosing adjustment for serum 25(OH)D level between 20 to 30 ng/mL and patient adherence established (Step 1 increase):
Infants:
Oral: 800 to 1,000 units/day
Children ≤10 years:
Oral: 1,600 to 3,000 units/day
Children >10 years and Adolescents:
Oral: 1,600 to 6,000 units/day
Dosing adjustment for serum 25(OH)D level <20 ng/mL or persistently between 20 to 30 ng/mL and patient adherence established (Step 2 increase):
Infants: Increase up to a maximum 2,000 units/day
Children ≤10 years: Increase to a maximum of 4,000 units/day
Children >10 years and Adolescents: Increase to a maximum of 10,000 units/day
Alternate dosing (Hall 2010):
Initial dose: Serum 25(OH)D level ≤30 ng/mL
Infants:
Oral: 8,000 units/
weekChildren and Adolescents:
Oral: 800 units/day
Medium-dose regimen: Serum 25(OH)D level remains ≤30 ng/mL and patient compliance established
Infants and Children <5 years:
Oral: 12,000 units/week for 12 weeks
Children ≥5 years and Adolescents:
Oral: 50,000 units/week for 12 weeks
High-dose regimen: Repeat 25(OH)D level remains ≤30 ng/mL and patient compliance established
Infants and Children <5 years:
Oral: 12,000 units twice weekly for 12 weeks
Children ≥5 years and Adolescents:
Oral: 50,000 units twice weekly for 12 weeks
Vitamin D insufficiency or deficiency associated with CKD (stages 2 to 5, 5D), treatment; serum 25 hydroxyvitamin D [25(OH)D] level ≤30 ng/mL (KDOQI Guidelines 2009):
Oral:
Serum 25(OH)D level 16 to 30 ng/mL: Infants, Children, and Adolescents: 2,000 units/day for 3 months or 50,000 units every month for 3 months
Serum 25(OH)D level 5 to 15 ng/mL: Infants, Children, and Adolescents: 4,000 units/day for 12 weeks or 50,000 units every other week for 12 weeks
Serum 25(OH)D level <5 ng/mL: Infants, Children, and Adolescents: 8,000 units/day for 4 weeks then 4,000 units/day for 2 months for total therapy of 3 months or 50,000 units/week for 4 weeks followed by 50,000 units 2 times/month for a total therapy of 3 months
Maintenance dose [once repletion accomplished; serum 25(OH)D level >30 ng/mL]: Infants, Children, and Adolescents: 200 to 1,000 units/day
Nutritional rickets, treatment: Limited data available (Munns 2016): Administer in combination with calcium supplementation:
Daily therapy (preferred):
Infants:
Oral: 2,000 units daily for ≥3 months, followed by maintenance dose of 400 units daily
Children:
Oral: 3,000 to 6,000 units daily for ≥3 months, followed by maintenance dose of 600 units daily
Adolescents:
Oral: 6,000 units daily for ≥3 months, followed by maintenance dose of 600 units daily
Single-dose therapy:
Infants ≥3 months:
Oral: 50,000 units once, or in divided doses over several days; after 3 months, initiate maintenance dose of 400 units daily
Children:
Oral: 150,000 units once, or in divided doses over several days; after 3 months, initiate maintenance dose of 600 units daily
Adolescents:
Oral: 300,000 units once, or in divided doses over several days; after 3 months, initiate maintenance dose of 600 units daily
Vitamin D interactions
Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. Avoid combination
Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations. Consider therapy modification
Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs. Monitor therapy
Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. Monitor therapy
Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs. Monitor therapy
Erdafitinib: Serum Phosphate Level-Altering Agents may diminish the therapeutic effect of Erdafitinib. Management: Avoid coadministration of serum phosphate level-altering agents with erdafitinib before initial dose increase period based on serum phosphate levels (Days 14 to 21). Consider therapy modification
Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations. Consider therapy modification
Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs. Avoid combination
Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs. Avoid combination
Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat. If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat. Consider therapy modification
Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. Avoid combination
Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs. Monitor therapy
Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs. Avoid combination
Vitamin D side effects
See also:
What are the possible side effects of Vitamin D?
*bone pain, hard lumps under your skin;
*eyes that are more sensitive to light;
*eye redness or discharge;
*weight loss;
*urinating more than usual, especially at night;
*nausea, vomiting;
Continue using dihydrotachysterol and talk with your doctor if you have any of these less serious side effects:
*changes in your bowel habits;
*dry mouth; or
*muscle pain.
Vitamin D contraindications
OTC labeling: Replesta products only: When used for self-medication, do not use if you have hypercalcemia, primary hyperparathyroidism, sarcoidosis, hypervitaminosis D, Williams syndrome, or are pregnant.
Documentation of allergenic cross-reactivity for vitamin D is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.
Active ingredient matches for Vitamin D:
Vitamin d/related compounds in Canada, United States.
Colecalciferol in Canada, United States.
Ergocalciferol in United States.
| Unit description / dosage (Manufacturer) | Price, USD |
| Capsule; Oral; Vitamin D2 / Ergocalciferol 50, 000 IU | |
| Tablet; Oral; Vitamin D3 / Cholecalciferol 400 units | |
| Capsule; Oral; Vitamin D3 / Cholecalciferol 200 units | |
| Tablet; Oral; Vitamin D3 / Cholecalciferol 1, 000 units | |
| Tablet; Oral; Vitamin D 400 units | |
| Vitamin D capsule 1.25 mg/1 (Aphena Pharma Solutions Tennessee, Llc (US)) | |
| Vitamin D capsule, liquid filled 1.25 mg/1 (Paddock Laboratories, LLC (US)) | |
| Vitamin D capsule 1.25 1/1 (Strides Arcolab Limited (US)) | |
List of Vitamin D substitutes (brand and generic names): | |
| Vitamin D3 Sandoz 500 I.E. (Switzerland) | |
| Vitamin D3 Streuli (Switzerland) | |
| Vitamin D3 Streuli 4000 IE/ml Prophylaxe (Switzerland) | |
| Vitamin D3 Streuli 4000 IE/ml Therapie (Switzerland) | |
| Vitamin D3 US Nutrition (Latvia) | |
| Vitamin D3 Wild (Switzerland) | |
| Vitamin D3 Wild 500 IE/Tropfen (Switzerland) | |
| Vitamin D3-Doms Adrian (Luxembourg) | |
| Vitamin D3-Hevert (Germany) | |
| Vitamin D3-Wörwag (Germany) | |
| Vitamina D (Brazil) | |
| Vitamina D Arion Mason (Peru) | |
| Vitamina D Pharma Arte (Paraguay) | |
| Vitamina D Richmond (Argentina) | |
| Vitamina D2 Salf (Italy) | |
| Vitamina D3 (Romania) | |
| Vitamina D3 Berenguer (Spain) | |
| Vitamina D3 Kern Pharma (Spain) | |
| Vitamine D Pro Doc (Canada) | |
| Vitamine D3 (Netherlands) | |
| Vitamine D3 1 ME/ml (Netherlands) | |
| Vitamine D3 1000 (Netherlands) | |
| Vitamine D3 B.O.N (South Korea) | |
| Vitamine D3 B.O.N 5 mg x 1 tube x 1 mL | |
| Vitamine D3 BON (Algeria, France, Lithuania, Sri Lanka, Tunisia, Vietnam) | |
| Injectable; Injection; Vitamin D3 / Cholecalciferol 5 mg / ml | |
| Vitamine D3 Internis (Netherlands) | |
| Vitamine D3 Kwang Dong (South Korea) | |
| Vitamins D3 Walmark (Latvia) | |
| Vitatabs Puru D (Latvia) | |
| Vitde (Chile) | |
| Vitergin (Argentina) | |
| Vitersol D (Brazil) | |
| Wal-D3 (India) | |
| Wal-D3 400IU x 5mL SYR / 60ml (Wallace (Lyfestyle)) | $ 0.72 |
| Wal-D3 60000 IU SG-CAP / 4 (Wallace (Lyfestyle)) | $ 1.57 |
| WAL-D3 syr 400 IU x 5 mL x 60ml (Wallace (Lyfestyle)) | $ 0.72 |
| WAL-D3 soft-gelatin cap 60000 IU x 4's (Wallace (Lyfestyle)) | $ 1.57 |
| Xarenel (Italy) | |
| Your Life Vitamin D3 (Latvia) | |
| YourHealth D3-1000 Vitamin D3 (Australia) | |
| Zymad (France) | |
| Solution; Oral; Vitamin D3 / Cholecalciferol 80, 000 IU (Novartis sante) | |
| Solution; Oral; Vitamin D3 / Cholecalciferol 200, 000 IU (Novartis sante) | |
| Solution; Oral; Vitamin D3 / Cholecalciferol 1, 000, 000 IU (Novartis sante) | |
See 523 substitutes for Vitamin D | |
References
- DailyMed. "ERGOCALCIFEROL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "CALCITRIOL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "CALCIFEDIOL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Vitamin D are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Vitamin D. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
1 consumer reported useful
Was the Vitamin D drug useful in terms of decreasing the symptom or the disease?According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
| Users | % | ||
|---|---|---|---|
| Not useful | 1 | 100.0% | |
1 consumer reported price estimates
Was the price you paid to purchase the drug reasonable? Did you feel it was expensive?The below mentioned numbers have been reported by ndrugs.com website users about whether the Vitamin D drug is expensive or inexpensive. There is a mixed opinion among users. The rating about the cost of the drug depends on factors like which brand drug the patient purchased, how effective it was for the price paid, the country or place the drug is marketed, and the economic condition of the patient. The users who feel the drug is expensive can look for an alternative brand drug or a generic drug to save the cost.
| Users | % | ||
|---|---|---|---|
| Not expensive | 1 | 100.0% | |
1 consumer reported time for results
To what extent do I have to use Vitamin D before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes 1 month and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Vitamin D. To get the time effectiveness of using Vitamin D drug by other patients, please click here.
| Users | % | ||
|---|---|---|---|
| 1 month | 1 | 100.0% | |
Consumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
